Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
Phase 2
Completed
NCT04205409
| Condition | Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | University of Washington |
|---|
| Status | Completed |
|---|
| Enrollment | 20 participants |
|---|
| Interventions | Nivolumab |
|---|
| Start date | Jun 5, 2020 |
|---|
| Completion date | Sep 20, 2024 |
|---|
| Results posted | Nov 3, 2025 |
|---|
Summary
This phase II trial studies how well nivolumab works for the treatment of hematological malignancies that have come back (relapsed), does not respond (refractory), or is detectable after CAR T cell therapy. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Best Overall Response Rate (ORR)
Up to 1 year and 8 months · Participants
| Treatment (Nivolumab) | 3 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.